Cash-strapped Arcadia seeks DailyMed buyer
The Indianapolis-based company is searching for a buyer for its once-promising DailyMed pharmacy service as it struggles to pay $30 million in debt that comes due in April.
Health Care Businesses
Articles
Potential Effient rival shows promise in study
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
Lilly files suit over flea medication sales from Australia
The Indianapolis-based pharmaceutical firm claims an Australian veterinary clinic is infringing on its Comfortis flea medication’s trademark by reselling it to U.S. consumers online.
Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
Lilly loses British Supreme Court ruling over gene patent
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
Insurer Humana’s quarterly profit climbs 13 percent
Humana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint Inc.
Ortho firms pull back on doc payments
The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Hill-Rom sees better earnings, revenue in quarter
Hill-Rom Holdings Inc. posted better-than-expected earnings and revenue in its fiscal fourth quarter, the Batesville-based hospital-bed supplier announced Wednesday.
Lilly diabetes drug wins approval for expanded use
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
Lilly announces replacements for two retiring executives
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
Lilly CEO says he’s not interested in Pfizer animal unit
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
Q&A
Dr. Ed Kowlowitz, owner and medical director of the Center for Pain Management in Indianapolis, recently challenged a regional Medicare reimbursement policy and, surprisingly, won. He spoke with IBJ about the experience, as well how his three-physician practice is growing even while many physician practices are selling to hospitals.
Lilly’s Alimta get favorable opinion for new use in Europe
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
Carmel-based company buys medical-billing firm
Zotec Partners, a fast-growing physician-billing management company based in Carmel, has acquired a family-owned medical-billing firm with 100 employees based in Florida.
FDA gets new report on Lilly diabetes drug
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
FDA deal with drugmakers raises user fees 6 percent
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
Private firm with Medicaid deal gets state help
Officials with the Missouri Department of Health and Senior Services say they had to hire 13 temporary workers and shift as many as 20 state workers from their regular jobs after withering consumer complaints against SynCare LLC of Indiana.
Missouri health care advocates decry Indiana contractor
Indianapolis-based SynCare LLC, hired to determine the eligibility of Missouri Medicaid patients for in-home care, has "been a complete disaster from the beginning," statewide health care advocates charge.